Daily Medication Pearl: Budesonide, Glycopyrrolate, and Formoterol Fumarate (Breztri)

Breztri is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease.

Medication Pearl of the Day: Budesonide, Glycopyrrolate, and Formoterol Fumarate (Breztri)

Indication: Budesonide, glycopyrrolate, and formoterol fumarate (Breztri) is a combination of budesonide, an inhaled corticosteroid; glycopyrrolate, an anticholinergic; and formoterol fumarate, a long-acting beta2-adrenergic agonist, indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

Insight:

  • Dosing: For maintenance treatment of COPD, 2 inhalations of Breztri Aerosphere twice daily administered by oral inhalation.
  • Dosage forms: Inhalation aerosol: Pressurized metered dose inhaler containing a combination of budesonide (160 mcg), glycopyrrolate (9 mcg), and formoterol fumarate (4.8 mcg) per inhalation.
  • Adverse events: Most common adverse reactions (incidence ≥ 2%) are upper respiratory tract infection, pneumonia, back pain, oral candidiasis, influenza, muscle spasm, urinary tract infection, cough, sinusitis, and diarrhea.
  • Mechanism of action: Breztri contains budesonide, glycopyrrolate, and formoterol fumarate- a corticosteroid, a long-acting muscarinic agent and a long-acting beta agonist.
  • Manufacturer: AstraZeneca

Reference: label (fda.gov)